CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance

By Reuters News


Overview

  • US biopharma firm's Q3 ARCALYST revenue rose 58% yr/yr to $286 mln

  • Net income for Q3 more than doubled to $47.3 mln from $18.4 mln last year

  • Company raised 2026 ARCALYST revenue guidance to $1.045-$1.050 bln


Outlook

  • Kiniksa raises 2026 ARCALYST net product revenue guidance to $1.045-$1.050 bln

  • Company expects 2026 R&D expenses of $160-$170 mln and SG&A expenses of $270-$280 mln

  • Company expects to remain cash flow positive on an annual basis under current operating plan


Result Drivers

  • ARCALYST ADOPTION - Co said strong commercial execution led to gains in patient and physician adoption of ARCALYST for recurrent pericarditis

  • OPERATING EXPENSES - Co said higher operating expenses were mainly due to increased ARCALYST sales and investment in commercialization

  • R&D SPENDING - Co said increased R&D expenses were mainly due to higher KPL-387 clinical activity


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Product Revenue

$285.97 mln

Q3 EPS

$0.56

Q3 Net Income

$47.35 mln

Q3 Operating Expenses

$231.73 mln

Q3 Pretax Profit

$59.06 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International, PLC is $98.00, about 34.3% above its October 26 closing price of $72.98

  • The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 42 three months ago


Reuters Recommended Reads

  • Oct 27 - Nautilus Biotechnology Q3 revenue beats

  • Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss

  • Oct 24 - Amgen drug combined with immunotherapy extends survival in lung cancer trial


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.